| Title |
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials
|
|---|---|
| Published in |
Cancer Management and Research, January 2015
|
| DOI | 10.2147/cmar.s72814 |
| Pubmed ID | |
| Authors |
Svetlana Kotova, Raymond M Wong, Robert B Cameron |
| Abstract |
Malignant pleural mesothelioma (MPM) is a rare tumor that is challenging to control. Despite some benefit from using the multimodality-approach (surgery, combination chemotherapy and radiation), survival remains poor. However, current research produced a list of potential therapies. Here, we summarize significant new preclinical and early clinical developments in treatment of MPM, which include mesothelin specific antibody and toxin therapies, interleukin-4 (IL-4) receptor toxins, dendritic cell vaccines, immune checkpoint inhibitors, and gene-based therapies. In addition, several local modalities such as photodynamic therapy, postoperative lavage using betadine, and cryotherapy for local recurrence, have also shown to be effective for local control of disease. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 40% |
| India | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 2% |
| Korea, Republic of | 1 | 2% |
| Unknown | 57 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 20% |
| Researcher | 8 | 14% |
| Student > Master | 8 | 14% |
| Student > Postgraduate | 6 | 10% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 11 | 19% |
| Unknown | 9 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 47% |
| Agricultural and Biological Sciences | 8 | 14% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Engineering | 2 | 3% |
| Other | 3 | 5% |
| Unknown | 11 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2018.
All research outputs
#2,131,648
of 22,789,076 outputs
Outputs from Cancer Management and Research
#50
of 1,995 outputs
Outputs of similar age
#31,564
of 352,984 outputs
Outputs of similar age from Cancer Management and Research
#1
of 6 outputs
Altmetric has tracked 22,789,076 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,995 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,984 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them